Laurence Albiges, MD, PhD, from the Gustave Roussy Institute, Villejuif, France discusses promising new trials in the treatment of renal cell carcinoma at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. The results of the randomised Phase II Emulsion trial (NCT02498665) and the Phase III CheckMate 214 (NCT02231749) investigating the combination of VEGF inhibitors and PDL1 inhibitors will soon be released. These results have the potential to challenge the first-line standard of care.